Form 4: Biora Therapeutics Director Howe Receives Stock Options and Restricted Stock Units

Director Jill Ann Howe acquired 12,500 stock options and 12,500 restricted stock units in Biora Therapeutics, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Jill Ann Howe, a director of Biora Therapeutics, Inc., acquired 12,500 shares of common stock in the form of restricted stock units.
• These restricted stock units vest fully on the earlier of June 5, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, contingent upon continued service to the Issuer.
• Howe also acquired options to purchase 12,500 shares of Biora Therapeutics' common stock at an exercise price of $0.70 per share.
• These options also vest fully on the earlier of June 5, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, contingent upon continued service to the Issuer.
• Following these transactions, Howe directly owns 31,916 shares of common stock and options to purchase 12,500 shares.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns director interests with shareholder value. The sentiment is moderately positive.

Positives

• The acquisition of stock options and restricted stock units by a director may signal confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the Reporting Person's continued service to the Issuer, suggesting an incentive for continued involvement with the company.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the granting of stock options and restricted stock units as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates

Keywords

Biora Therapeutics, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, BIOR, Vesting